snoRNA87在原发性肝癌中的表达及意义  

Study on the expression and significance of small nucleolar RNA 87 in primary hepatocellular carcinoma

作　　者：孙菲[1] 张金仿[1] 王克迪[1] 苏建荣[1] SUN Fei;ZHANG Jinfang;WANG Kedi;SU Jianrong(Clinical Laboratory,Beijing Friendship Hospital,Capital Medical University,Beijing 100050,China)

机构地区：[1]首都医科大学附属北京友谊医院检验科,北京100050

出　　处：《癌症进展》2020年第4期406-409,共4页Oncology Progress

摘　　要：目的探讨小核仁RNA87(snoRNA87)在原发性肝癌患者肝癌组织中的表达及意义。方法取100例原发性肝癌患者的肝癌组织及对应的癌旁组织,免疫组化法检测snoRNA87的阳性表达率,分析其与原发性肝癌患者临床特征的关系。荧光定量逆转录聚合酶链反应(RT-PCR)检测snoRNA87的相对表达量,并据此分为高表达组(n=62)和低表达组(n=38),Kaplan-Meier法绘制生存曲线,生存率的比较采Log-rank检验,比较两组患者平均生存时间、中位无进展生存期(PFS)和总生存期(OS)。探讨snoRNA87对原发性肝癌的诊断价值。结果肝癌组织中snoRNA87的阳性表达率为91%,明显高于癌旁组织的14%,差异有统计学意义(P<0.01)。不同分化程度、TNM分期、血清甲胎蛋白(AFP)浓度原发性肝癌患者肝癌组织中snoRNA87阳性表达率比较,差异均有统计学意义(P<0.05)。高表达组患者的5年生存率为14.52%(9/62),明显低于低表达组患者的42.11%(16/38),高表达组患者的5年平均生存时间为(2.13±0.50)年,明显短于低表达组患者的(3.56±1.01)年,差异均有统计学意义(P<0.01)。高表达组患者的中位PFS为10.6个月,长于低表达组患者4.5个月,中位OS为20.4个月,短于低表达组患者的32.2个月。snoRNA87诊断原发性肝癌的ROC曲线下面积(AUC)为0.734(0.577~0.980),当截断值为38.12时,诊断灵敏度为93.12%,特异度为94.25%;当截断值为17.59时,诊断灵敏度为97.58%,特异度为91.32%。结论snoRNA87在原发性肝癌患者肝癌组织中阳性表达率较高,且可能与原发性肝癌患者的分化程度、TNM分期和血清AFP浓度有关,对原发性肝癌的诊断价值较高。Objective To study the expression and clinical significance of small nucleolar RNA 87(snoRNA87)in patients with primary hepatocellular carcinoma(HCC).Method A total of 100 patients with primary HCC were included,from which the carcinoma tissues and adjacent normal tissues were collected and detected for the positive expression of snoRNA87 by immunohistochemistry assay,to determine the relationship between snoRNA 87 and clinical characteristics of primary HCC.The relative expression of snoRNA87 was detected by reverse transcriptase polymerase chain reaction(RT-PCR),and these specimens were further subclassified as high-expression group(n=62)and low-expression group(n=38),respectively;Kaplan-Meier method was applied to plot the survival curve,and Log-rank test was used to compare the survival rates,additionally,the mean survival time,median progression-free survival(PFS)and overall survival(OS)of the two groups of patients were also assessed and compared,finally,the diagnostic value of snoRNA87 for primary HCC was investigated.Result The positive expression rate of snoRNA87 in primary HCC tissues was 91%,which was significantly higher than that in adjacent normal tissues at 14%,with statistically significant difference observed(P<0.01).The positive expression of snoRNA87 was significantly associated with the clinical characteristics including differentiation degree,TNM stage,and serum a-fetoprotein(AFP)concentration of primary HCC patients.The 5-year survival rate in high-expression group was 14.52%(9/62),and it was lower compared to the 42.11%(16/38)in lowexpression group,with statistically significant difference noted(P<0.01);the mean 5-year survival time was(2.12±0.50)years versus(3.56±1.01)years in high-and low-expression groups respectively,besides,the median PFS was 10.6 months and median OS was 20.4 months in high-expression group versus 4.5 months and 32.2 months in low-expression group,correspondingly.The area under receiver operating characteristics(ROC)curve(AUC)of snoRNA87 for the diagnosis of primary

关 键 词：snoRNA87 原发性肝癌 生存周期 

分 类 号：R735.7[医药卫生—肿瘤]